Navigation Links
Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
Date:5/16/2008

ous placebo. Study results showed that the use of calcium and magnesium infusions before and after oxaliplatin was associated with a significant decrease in the incidence and severity of neurotoxicity, and it also delayed the time to the onset of neurotoxicity on oxaliplatin therapy.

Calcium and magnesium are an easily administered, safe treatment option for oxaliplatin-induced neurotoxicity. Some initial reports from other studies claimed that the use of calcium and magnesium reduced the activity of oxaliplatin-based chemotherapy, says Axel Grothey, M.D., an oncologist at Mayo Clinic and study co-chair. However, we have definitive results from an independent, blinded radiologic review which demonstrates no negative influence of calcium and magnesium on the outcome for oxaliplatin-based chemotherapy.

Now that we have shown the effectiveness of calcium and magnesium in reducing oxaliplatin-induced neurotoxicity, a further step may be to evaluate the benefit of calcium and magnesium in reducing neurotoxicity caused by other medications, says Dr. Nikcevich. Many other commonly used chemotherapy agents cause neurological sensitivity. By applying our study design, we can test the effectiveness of calcium and magnesium when used with other treatments.

This study was done as part of a program coordinated by Charles Loprinzi, M.D., a medical oncologist at Mayo Clinic Rochester. The program he leads has conducted more than 50 clinical trials designed to find ways to prevent or treat untoward symptoms related to cancer and cancer therapy. This includes three trials to evaluate ways to treat established neuropathy caused by chemotherapy and three additional studies to try to prevent such toxicity. Additional trials are in development to find other ways to alleviate this toxicity.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
2. Study suggests blood test can help improve treatment outcomes for breast cancer patients
3. Study takes a step toward better defining fatigue
4. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
5. Study finds parents use cough medicines on under-2s despite the warnings
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. Study Supports Popular HIV Drug Regimen
8. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
9. Study shows that prostate cancer increases the risk of bone fracture
10. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
11. Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Wellesley, Mass., (PRWEB) September 01, 2014 ... report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS ... reached $21.8 million in 2013 and is expected to ... further grow to $471.5 million by 2019, which is ... 2014 through 2019. The receptor-mediated transport (RMT) segment is ...
(Date:9/1/2014)... 2014 Parties involved in federally-filed Tylenol ... litigation’s status conference in September, where issues related to ... the Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... posted on the Court’s website, the meeting is scheduled ... a.m. This is the latest of several Tylenol conferences ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on DePuy Synthes Craniomaxillofacial Distraction System ... 28, that specific lots of DePuy Synthes Craniomaxillofacial Distraction ... device may reverse directions after surgery. According to ... is an implant used to lengthen and/or stabilize the ...
(Date:9/1/2014)... 01, 2014 Beginning Tuesday, September 2nd, ... medical professionals and 10,000 consumers for the annual gathering ... gathering of the nation’s top medical professionals who specializes ... conditions. The week-long event contains more than 120 hours ... available in the pain management field. , MarijuanaDoctors.com is ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2
... the largest study of its kind for the genetic roots ... Disease as well as further evidence that some people of ... study examined changes in DNA associated with the two most ... which is most frequently marked by inflammation of the final ...
... Assessment Tools To ... Healthier Lifestyles, NEW YORK, March 26 EnergyNow!, ... and fitness,technology fields, today announced the availability of a ... Delaware, Maryland,Pennsylvania, Virginia, West Virginia and Washington D.C. combat ...
... Governor Edward G.,Rendell today announced the state,s new ... ahead to better meet their future,long-term care needs., ... be put off. If,people do fail to prepare, it ... "The ,Own Your Future, campaign,empowers consumers to take steps ...
... Award-Winning Mind Fitness Company, WASHINGTON, March 26 ... Ltd., the company that uses the latest scientific,research ... cognitive,performance and health, today announced that it will ... the American Society on Aging,(ASA), as a consultant., ...
... Technologies(R),Inc. ("Global Med" or the "Company") (OTC Bulletin ... announced,the sale yesterday, March 25, 2008, of approximately ... was held by SingXpress Ltd., an Asian company,(previously ... were sold,to five American institutions and the transaction ...
... lower health-related quality of life for their children ... from the parents of healthy children. However, reports ... These findings are published in the April issue ... online at Wiley Interscience (www.interscience.wiley.com ). , Children ...
Cached Medicine News:Health News:Large multicenter study suggests new genetic markers for Crohn's disease 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 3Health News:Governor Rendell Announces 'Own Your Future' Campaign; Urges Consumers to Better Plan Their Long-Term Care Needs 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Global Med Technologies(R), Inc. Announces the Sale of Approximately 3.3 Million Shares of Global Med Common Stock Held by SingXpress Ltd., an Asian Company, to Five American Institutions 2Health News:Study shows lifetime effects of pediatric liver transplants 2
(Date:9/1/2014)... Reportlinker.com announces that ... its catalogue: Antibody Drug Conjugates Market ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html INTRODUCTION Antibody ... therapeutic agents, gaining increasing attention from both large ... marriage of an antibody with a toxic drug ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM ... (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that ... recall to address a potential issue with a ... for the Axilla application of the SAM Junctional ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... , TUCSON, Ariz. , Feb. 4 ... care. Arizona Oncology physicians will now treat patients at Marana Healthcare Clinic ... medical oncologists, are now actively caring for patients at MHC. , "We ... "By providing cancer care services in Marana we are able ...
... , SUNNYVALE, Calif. , Feb. 4 ... of radiosurgery, announced today financial results for the second quarter of fiscal ... second quarter of fiscal 2010, Accuray reported total revenue of $57.3 ... of $57.6 million . , Accuray reported a net loss ...
Cached Medicine Technology:Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 2Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 3Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 4Accuray Announces Results for Second Quarter Fiscal 2010 2Accuray Announces Results for Second Quarter Fiscal 2010 3Accuray Announces Results for Second Quarter Fiscal 2010 4Accuray Announces Results for Second Quarter Fiscal 2010 5Accuray Announces Results for Second Quarter Fiscal 2010 6Accuray Announces Results for Second Quarter Fiscal 2010 7Accuray Announces Results for Second Quarter Fiscal 2010 8Accuray Announces Results for Second Quarter Fiscal 2010 9Accuray Announces Results for Second Quarter Fiscal 2010 10Accuray Announces Results for Second Quarter Fiscal 2010 11Accuray Announces Results for Second Quarter Fiscal 2010 12
... Lyphochek Immunoassay Plus Control provides ... comprehensive control in the world for ... procedures, eliminating the need for separate ... no added preservatives, it is suitable ...
... Plus Control is a liquid ... today's busy immunoassay laboratory. With ... human serum based control can ... control products for immunoassay and ...
Liquichek Immunology Control is a trilevel, liquid, comprehensive serum protein control with assayed values for a wide number of methods....
... Detection Platform provides fully automated detection of ... platform for molecular pathology labs separates DNA ... features that deliver a high degree of ... the capacity to run two 96-well plates, ...
Medicine Products: